The two novel LIMK inhibitors described in the present study, CRT0105446 and CRT0105950, are potent inhibitors of LIMK1 and LIMK2 that will enable further development of LIMK-targeted cancer therapy. The gene discussed is LIMK1; the disease is cancer.